Loading clinical trials...

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

NCT01983410•Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•BRCA mutation carrier is defined as a person with any mutation of the BRCA gene, including BRCA1, or BRCA2. PALB2mut patients are also eligible.
•Relative of a BRCA PDAC patient is defined as a first-degree relative, which includes, parents, siblings or children.
•BRCAmut PDAC Group: Study Group A: Ashkenazi Jewish descent
•Known BRCA mutation carrier.
•Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
•Histologic proof of primary pancreatic ductal adenocarcinoma.
•May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
•Prior personal history of other malignancy; either prior or currently active, including breast , ovarian or prostate cancer is allowed.
•Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
•Willing to provide blood specimens for correlative studies.
+51 more criteria

Exclusion Criteria

•Individuals will be excluded from the Registry if they:
•Are unable to sign informed consent for medical or other reasons. Do not speak English (MSK and UPenn) or do not speak English or Hebrew (BCGC Sites).
•Are under 21 years of age.
•Not willing to provide blood samples for correlative studies.

Locations (13)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Cold Springs Harbor Laboratory (Specimen Analysis)

Cold Spring Harbor, New York, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Weill Cornell Medical College (Specimen Analysis)

New York, New York, United States

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

Abramson Cancer Center at University of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

November 4, 2013

Primary Completion Date

November 1, 2026

Completion Date

November 1, 2026

Last Updated

December 30, 2025

Enrollment

600

ESTIMATED participants

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

The risk assessment questionnaire

BEHAVIORAL

Blood specimens

OTHER

tumor tissue samples will be requested

OTHER

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1/PHASE2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Colorectal CancerCRC+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors